Table 2 linear mixed-effects model results for association between KIR/HLA and HIV viraemia in 139 women with incident HIV infection followed up for up to 10 years post infection

Fixed effects

Haplotype

AA

4.52

Ref

0.15

0.03

AB

−0.08

0.15

BB

−0.44

0.18

KIR loci

KIR2DL2/KIR2DL2

4.08

Ref

0.15

0.02

KIR2DL2/KIR2DL3

0.33

0.16

KIR2DL3/KIR2DL3

0.46

0.17

KIR2DL5

4.43

−0.13

0.13

0.32

KIR3DL1/KIR3DL1

4.33

Ref

0.10

0.84

KIR3DL1/KIR3DS1

−0.05

0.24

KIR3DS1/KIR3DS1

-

-

-

KIR2DS1

4.36

−0.13

0.19

0.47

KIR2DS2

4.53

−0.28

0.13

0.03

KIR2DS3/KIR2DS3

4.03

Ref

0.19

0.14

KIR2DS3/KIR2DS5

0.01

0.25

KIR2DS5/KIR2DS5

0.33

0.20

KIR2DS4

4.43

−0.08

0.77

0.91

HLA groups

Protective HLA-B alleles

4.38

−0.27

0.17

0.10

Harmful HLA-B alleles

4.26

0.25

0.13

0.06

Bw4

4.33

0.07

0.14

0.63

Bw6

4.39

−0.08

0.13

0.52

Number of C1 epitopes

4.40

−0.08

0.09

0.40

Number of C2 epitopes

4.25

0.07

0.09

0.43

Random Effects

Variance

SD

Weeks postinfection

(Intercept)

0.02

0.12

X002PID

(Intercept)

0.61

0.78

Residual

0.31

0.55